HLA Class I and II Diversity Contributes to the Etiologic
Heterogeneity of Non-Hodgkin Lymphoma Subtypes

J 2018

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

WANG, S.S., M. CARRINGTON, S.I. BERNDT, S.L. SLAGER, P.M. BRACCI et. al.

Základní údaje

Originální název

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

Autoři

WANG, S.S. (840 Spojené státy), M. CARRINGTON (840 Spojené státy), S.I. BERNDT (840 Spojené státy), S.L. SLAGER (840 Spojené státy), P.M. BRACCI (840 Spojené státy), J. VOUTSINAS (840 Spojené státy), J.R. CERHAN (840 Spojené státy), K.E. SMEDBY (840 Spojené státy), H. HJALGRIM (208 Dánsko), J. VIJAI (840 Spojené státy), L.M. MORTON (840 Spojené státy), R. VERMEULEN (528 Nizozemské království), O. PALTIEL (376 Izrael), C.M. VAJDIC (36 Austrálie), M.S. LINET (840 Spojené státy), A. NIETERS (276 Německo), S. de SANJOSE (724 Španělsko), W. COZEN (840 Spojené státy), E.E. BROWN (840 Spojené státy), J. TURNER (36 Austrálie), J.J. SPINELLI (124 Kanada), T.Z. ZHENG (840 Spojené státy), B.M. BIRMANN (840 Spojené státy), C.R. FLOWERS (840 Spojené státy), N. BECKER (276 Německo), E.A. HOLLY (840 Spojené státy), E. KANE (826 Velká Británie a Severní Irsko), D. WEISENBURGER (840 Spojené státy), M. MAYNADIE (250 Francie), P. COCCO (380 Itálie), D. ALBANES (840 Spojené státy), S.J. WEINSTEIN (840 Spojené státy), L.R. TERAS (840 Spojené státy), W.R. DIVER (840 Spojené státy), S.J. LAX (826 Velká Británie a Severní Irsko), R.C. TRAVIS (826 Velká Británie a Severní Irsko), R. KAAKS (276 Německo), E. RIBOLI (826 Velká Británie a Severní Irsko), Y. BENAVENTE (826 Velká Británie a Severní Irsko), P. BRENNAN (724 Španělsko), J. MCKAY (250 Francie), M.H. DELFAU-LARUE (250 Francie), B.K. LINK (840 Spojené státy), C. MAGNANI (380 Itálie), M.G. ENNAS (380 Itálie), G. LATTE (380 Itálie), A.L. FELDMAN (840 Spojené státy), N.W. DOO (36 Austrálie), G.G. GILES (36 Austrálie), M.C. SOUTHEY (36 Austrálie), R.L. MILNE (36 Austrálie), K. OFFIT (208 Dánsko), J. MUSINSKY (208 Dánsko), A.A. ARSLAN (840 Spojené státy), M.P. PURDUE (840 Spojené státy), H.O. ADAMI (752 Švédsko), M. MELBYE (840 Spojené státy), B. GLIMELIUS (752 Švédsko), L. CONDE (826 Velká Británie a Severní Irsko), N.J. CAMP (840 Spojené státy), M. GLENN (840 Spojené státy), K. CURTIN (840 Spojené státy), J. CLAVEL (250 Francie), A. MONNEREAU (250 Francie), D.G. COX (826 Velká Británie a Severní Irsko), H. GHESQUIERES (250 Francie), G. SALLES (250 Francie), P. BOFETTA (840 Spojené státy), Lenka FORETOVÁ (203 Česká republika, domácí), A. STAINES (826 Velká Británie a Severní Irsko), S. DAVIS (840 Spojené státy), R.K. SEVERSON (840 Spojené státy), Q. LAN (840 Spojené státy), A. BROOKS-WILSON (124 Kanada), M.T. SMITH (840 Spojené státy), E. ROMAN (826 Velká Británie a Severní Irsko), A. KRICKER (36 Austrálie), Y.W. ZHANG (840 Spojené státy), P. KRAFT (840 Spojené státy), S.J. CHANOCK (840 Spojené státy), N. ROTHMAN (840 Spojené státy), P. HARTGE (840 Spojené státy) a C.F. SKIBOLA (840 Spojené státy)

Vydání

Cancer Research, PHILADELPHIA, AMER ASSOC CANCER RESEARCH, 2018, 0008-5472

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 8.378

Kód RIV

RIV/00216224:14110/18:00106857

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1158/0008-5472.CAN-17-2900

UT WoS

000439199100028

Klíčová slova anglicky

leukocyte antigen

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 23. 4. 2024 10:14, Mgr. Michal Petr

Anotace

V originále

A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of "heterozygote advantage" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. (C) 2018 AACR.

Citovat

WANG, S.S., M. CARRINGTON, S.I. BERNDT, S.L. SLAGER, P.M. BRACCI, J. VOUTSINAS, J.R. CERHAN, K.E. SMEDBY, H. HJALGRIM, J. VIJAI, L.M. MORTON, R. VERMEULEN, O. PALTIEL, C.M. VAJDIC, M.S. LINET, A. NIETERS, S. de SANJOSE, W. COZEN, E.E. BROWN, J. TURNER, J.J. SPINELLI, T.Z. ZHENG, B.M. BIRMANN, C.R. FLOWERS, N. BECKER, E.A. HOLLY, E. KANE, D. WEISENBURGER, M. MAYNADIE, P. COCCO, D. ALBANES, S.J. WEINSTEIN, L.R. TERAS, W.R. DIVER, S.J. LAX, R.C. TRAVIS, R. KAAKS, E. RIBOLI, Y. BENAVENTE, P. BRENNAN, J. MCKAY, M.H. DELFAU-LARUE, B.K. LINK, C. MAGNANI, M.G. ENNAS, G. LATTE, A.L. FELDMAN, N.W. DOO, G.G. GILES, M.C. SOUTHEY, R.L. MILNE, K. OFFIT, J. MUSINSKY, A.A. ARSLAN, M.P. PURDUE, H.O. ADAMI, M. MELBYE, B. GLIMELIUS, L. CONDE, N.J. CAMP, M. GLENN, K. CURTIN, J. CLAVEL, A. MONNEREAU, D.G. COX, H. GHESQUIERES, G. SALLES, P. BOFETTA, Lenka FORETOVÁ, A. STAINES, S. DAVIS, R.K. SEVERSON, Q. LAN, A. BROOKS-WILSON, M.T. SMITH, E. ROMAN, A. KRICKER, Y.W. ZHANG, P. KRAFT, S.J. CHANOCK, N. ROTHMAN, P. HARTGE a C.F. SKIBOLA. HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research. PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2018, roč. 78, č. 14, s. 4086-4096. ISSN 0008-5472. Dostupné z: https://dx.doi.org/10.1158/0008-5472.CAN-17-2900.

@article{1526399,
   author = {Wang, S.S. and Carrington, M. and Berndt, S.I. and Slager, S.L. and Bracci, P.M. and Voutsinas, J. and Cerhan, J.R. and Smedby, K.E. and Hjalgrim, H. and Vijai, J. and Morton, L.M. and Vermeulen, R. and Paltiel, O. and Vajdic, C.M. and Linet, M.S. and Nieters, A. and Sanjose, S. de and Cozen, W. and Brown, E.E. and Turner, J. and Spinelli, J.J. and Zheng, T.Z. and Birmann, B.M. and Flowers, C.R. and Becker, N. and Holly, E.A. and Kane, E. and Weisenburger, D. and Maynadie, M. and Cocco, P. and Albanes, D. and Weinstein, S.J. and Teras, L.R. and Diver, W.R. and Lax, S.J. and Travis, R.C. and Kaaks, R. and Riboli, E. and Benavente, Y. and Brennan, P. and McKay, J. and DelfauandLarue, M.H. and Link, B.K. and Magnani, C. and Ennas, M.G. and Latte, G. and Feldman, A.L. and Doo, N.W. and Giles, G.G. and Southey, M.C. and Milne, R.L. and Offit, K. and Musinsky, J. and Arslan, A.A. and Purdue, M.P. and Adami, H.O. and Melbye, M. and Glimelius, B. and Conde, L. and Camp, N.J. and Glenn, M. and Curtin, K. and Clavel, J. and Monnereau, A. and Cox, D.G. and Ghesquieres, H. and Salles, G. and Bofetta, P. and Foretová, Lenka and Staines, A. and Davis, S. and Severson, R.K. and Lan, Q. and BrooksandWilson, A. and Smith, M.T. and Roman, E. and Kricker, A. and Zhang, Y.W. and Kraft, P. and Chanock, S.J. and Rothman, N. and Hartge, P. and Skibola, C.F.},
   article_location = {PHILADELPHIA},
   article_number = {14},
   doi = {http://dx.doi.org/10.1158/0008-5472.CAN-17-2900},
   keywords = {leukocyte antigen},
   language = {eng},
   issn = {0008-5472},
   journal = {Cancer Research},
   title = {HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes},
   url = {http://dx.doi.org/10.1158/0008-5472.CAN-17-2900},
   volume = {78},
   year = {2018}
}

TY  - JOUR
ID  - 1526399
AU  - Wang, S.S. - Carrington, M. - Berndt, S.I. - Slager, S.L. - Bracci, P.M. - Voutsinas, J. - Cerhan, J.R. - Smedby, K.E. - Hjalgrim, H. - Vijai, J. - Morton, L.M. - Vermeulen, R. - Paltiel, O. - Vajdic, C.M. - Linet, M.S. - Nieters, A. - Sanjose, S. de - Cozen, W. - Brown, E.E. - Turner, J. - Spinelli, J.J. - Zheng, T.Z. - Birmann, B.M. - Flowers, C.R. - Becker, N. - Holly, E.A. - Kane, E. - Weisenburger, D. - Maynadie, M. - Cocco, P. - Albanes, D. - Weinstein, S.J. - Teras, L.R. - Diver, W.R. - Lax, S.J. - Travis, R.C. - Kaaks, R. - Riboli, E. - Benavente, Y. - Brennan, P. - McKay, J. - Delfau-Larue, M.H. - Link, B.K. - Magnani, C. - Ennas, M.G. - Latte, G. - Feldman, A.L. - Doo, N.W. - Giles, G.G. - Southey, M.C. - Milne, R.L. - Offit, K. - Musinsky, J. - Arslan, A.A. - Purdue, M.P. - Adami, H.O. - Melbye, M. - Glimelius, B. - Conde, L. - Camp, N.J. - Glenn, M. - Curtin, K. - Clavel, J. - Monnereau, A. - Cox, D.G. - Ghesquieres, H. - Salles, G. - Bofetta, P. - Foretová, Lenka - Staines, A. - Davis, S. - Severson, R.K. - Lan, Q. - Brooks-Wilson, A. - Smith, M.T. - Roman, E. - Kricker, A. - Zhang, Y.W. - Kraft, P. - Chanock, S.J. - Rothman, N. - Hartge, P. - Skibola, C.F.
PY  - 2018
TI  - HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes
JF  - Cancer Research
VL  - 78
IS  - 14
SP  - 4086-4096
EP  - 4086-4096
PB  - AMER ASSOC CANCER RESEARCH
SN  - 00085472
KW  - leukocyte antigen
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-17-2900
N2  - A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of "heterozygote advantage" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. (C) 2018 AACR.
ER  -

WANG, S.S., M. CARRINGTON, S.I. BERNDT, S.L. SLAGER, P.M. BRACCI, J. VOUTSINAS, J.R. CERHAN, K.E. SMEDBY, H. HJALGRIM, J. VIJAI, L.M. MORTON, R. VERMEULEN, O. PALTIEL, C.M. VAJDIC, M.S. LINET, A. NIETERS, S. de SANJOSE, W. COZEN, E.E. BROWN, J. TURNER, J.J. SPINELLI, T.Z. ZHENG, B.M. BIRMANN, C.R. FLOWERS, N. BECKER, E.A. HOLLY, E. KANE, D. WEISENBURGER, M. MAYNADIE, P. COCCO, D. ALBANES, S.J. WEINSTEIN, L.R. TERAS, W.R. DIVER, S.J. LAX, R.C. TRAVIS, R. KAAKS, E. RIBOLI, Y. BENAVENTE, P. BRENNAN, J. MCKAY, M.H. DELFAU-LARUE, B.K. LINK, C. MAGNANI, M.G. ENNAS, G. LATTE, A.L. FELDMAN, N.W. DOO, G.G. GILES, M.C. SOUTHEY, R.L. MILNE, K. OFFIT, J. MUSINSKY, A.A. ARSLAN, M.P. PURDUE, H.O. ADAMI, M. MELBYE, B. GLIMELIUS, L. CONDE, N.J. CAMP, M. GLENN, K. CURTIN, J. CLAVEL, A. MONNEREAU, D.G. COX, H. GHESQUIERES, G. SALLES, P. BOFETTA, Lenka FORETOVÁ, A. STAINES, S. DAVIS, R.K. SEVERSON, Q. LAN, A. BROOKS-WILSON, M.T. SMITH, E. ROMAN, A. KRICKER, Y.W. ZHANG, P. KRAFT, S.J. CHANOCK, N. ROTHMAN, P. HARTGE a C.F. SKIBOLA. HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. \textit{Cancer Research}. PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2018, roč.~78, č.~14, s.~4086-4096. ISSN~0008-5472. Dostupné z: https://dx.doi.org/10.1158/0008-5472.CAN-17-2900.

Podrobný výpis o publikaci